Published in Hepatology on September 01, 2008
Serum sodium and survival benefit of liver transplantation. Liver Transpl (2015) 1.75
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One (2015) 1.43
Model for end-stage liver disease: end of the first decade. Clin Liver Dis (2011) 1.20
Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol (2013) 1.15
Vaptans: A new option in the management of hyponatremia. Int J Appl Basic Med Res (2012) 1.11
Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc (2011) 0.98
Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transpl (2014) 0.95
Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. Curr Opin Gastroenterol (2010) 0.92
Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Crit Care (2014) 0.89
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia. Therap Adv Gastroenterol (2012) 0.86
Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol (2015) 0.84
Hyponatraemia and cirrhosis. Gastroenterol Rep (Oxf) (2014) 0.82
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Hyponatremia and Hepatorenal Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.79
Clinical use of albumin. Blood Transfus (2013) 0.79
Extracellular sodium dependence of the conduction velocity-calcium relationship: evidence of ephaptic self-attenuation. Am J Physiol Heart Circ Physiol (2016) 0.78
Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol (2015) 0.78
Hyperammonemia and systemic inflammatory response syndrome predicts presence of hepatic encephalopathy in dogs with congenital portosystemic shunts. PLoS One (2014) 0.78
Hepatic encephalopathy therapy: An overview. World J Gastrointest Pharmacol Ther (2010) 0.78
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. World J Gastroenterol (2014) 0.78
Systemic vascular resistance in cirrhosis: a predictor of severity? Hepat Med (2014) 0.78
Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer (2015) 0.77
Hyponatremia - predictor of adverse prognosis in cirrhosis. J Med Life (2012) 0.76
Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. World J Hepatol (2016) 0.76
Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med (2014) 0.76
Profound hyponatremia in cirrhosis: a case report. Cases J (2010) 0.75
Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation? Ann Intensive Care (2015) 0.75
Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide. Front Med (Lausanne) (2017) 0.75
Implications of Hyponatremia in Liver Transplantation. J Clin Med (2014) 0.75
Plasma Amino Acid Concentrations Predict Mortality in Patients with End-Stage Liver Disease. PLoS One (2016) 0.75
Model for end-stage liver disease-Na score or Maddrey discrimination function index, which score is best? World J Hepatol (2015) 0.75
Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt. Electron Physician (2015) 0.75
Hyponatremia is Associated with Fluid Imbalance and Adverse Renal Outcome in Chronic Kidney Disease Patients Treated with Diuretics. Sci Rep (2016) 0.75
Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci (2017) 0.75
Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect (2017) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol (2013) 3.41
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol (2013) 2.11
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Hepatorenal syndrome. Lancet (2003) 1.86
Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology (2006) 1.64
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med (2010) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (2010) 1.21
Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology (2002) 1.20
Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol (2012) 1.12
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09
Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology (2003) 1.05
LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol (2012) 0.98
Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol (2008) 0.98
Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol (2012) 0.98
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology (2004) 0.89
Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol (2012) 0.83
Hyponatremia in cirrhosis: clinical features and management. Gastroenterol Clin Biol (2006) 0.80
Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived. Hepatology (2007) 0.80
Reply to: "Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open". J Hepatol (2012) 0.78
Good news for hepatorenal syndrome. Hepatology (2002) 0.77
Management of hepatorenal syndrome: another piece of the puzzle. Hepatology (2004) 0.76
[Biomarkers of acute kidney injury: a « trending topic » in cirrhosis]. Gastroenterol Hepatol (2013) 0.75
[Hepatorenal syndrome]. Gastroenterol Hepatol (2007) 0.75
Recent advances in hepatorenal syndrome. Trop Gastroenterol (2005) 0.75